Amazon coin set to soar 25X – starting December 16th?

This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team of crypto experts has identified it as the most promising crypto of 2024. You can see all of the details surrounding the #1 Crypto of 2024

Joanne Jenkins Lager net worth and biography

Joanne Lager Biography and Net Worth

Insider of iTeos Therapeutics

Jo joined iTeos as Chief Medical Officer in April 2019.

Before joining iTeos, Jo had more than 15 years of experience in Oncology drug development at GSK and Sanofi, most recently as the Head of Global Oncology Development at Sanofi. Here, she was responsible for the entire Oncology portfolio from preclinical development through to post-marketing commitments and life-cycle management, significantly rebuilding the portfolio during her five years in this role. Jo earned her M.D. and trained as a Pediatric Hematologist/Oncologist at Duke University and practiced Pediatric Blood and Marrow Transplantation at Duke University Hospital. She has authored or co-authored 20 peer-reviewed publications.

How do I contact Joanne Jenkins Lager?: The corporate mailing address for Dr. Lager and other iTeos Therapeutics executives is , , . iTeos Therapeutics can also be reached via phone at 339-217-0161 and via email at [email protected]. Learn More on Joanne Jenkins Lager's contact information.
Has Joanne Jenkins Lager been buying or selling shares of iTeos Therapeutics?: Joanne Jenkins Lager has not been actively trading shares of iTeos Therapeutics over the course of the past ninety days. Most recently, Joanne Jenkins Lager sold 3,500 shares of the business's stock in a transaction on Friday, March 11th. The shares were sold at an average price of $36.01, for a transaction totalling $126,035.00. Learn More on Joanne Jenkins Lager's trading history.
Who are iTeos Therapeutics' active insiders?: iTeos Therapeutics' insider roster includes Detlev Biniszkiewicz (Director), Michel Detheux (CEO), Ansbert Gadicke (Major Shareholder), Matthew Gall (CFO), David Hallal (Director), Les Korsh (VP), Joanne Lager (Insider), and Yvonne McGrath (VP). Learn More on iTeos Therapeutics' active insiders.
Are insiders buying or selling shares of iTeos Therapeutics?: During the last year, iTeos Therapeutics insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $38,650.00. The most recent insider tranaction occured on November, 19th when CFO Matthew Gall bought 5,000 shares worth more than $38,650.00. Insiders at iTeos Therapeutics own 12.5% of the company. Learn More about insider trades at iTeos Therapeutics.
Information on this page was last updated on 11/19/2024.

Joanne Jenkins Lager Insider Trading History at iTeos Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
3/11/2022	Sell	3,500	$36.01	$126,035.00
2/11/2022	Sell	3,500	$35.85	$125,475.00
1/14/2022	Sell	3,500	$39.32	$137,620.00
1/3/2022	Sell	7,000	$51.90	$363,300.00
12/17/2021	Sell	7,000	$41.00	$287,000.00
12/10/2021	Sell	3,500	$34.50	$120,750.00
11/18/2021	Sell	28,000	$34.50	$966,000.00

Joanne Jenkins Lager Buying and Selling Activity at iTeos Therapeutics

iTeos Therapeutics Company Overview

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $7.42

$7.09

$7.51

50 Day Range

MA: $8.54

$7.22

$9.73

2 Week Range

Now: $7.42

$7.09

$18.75

Volume

2,443,768 shs

Average Volume

452,593 shs

Market Capitalization

$271.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37